As studies on LPA and APOC3 variants have established a causal link between their respective lipoprotein biomarker and increased risk of CV disease, [5, 6, 20, 22, 23] leveraging genetic data as an instrumental variable for CKD risk would more fully address reverse causation and exclude other confounders. This evidence concerns the gene APOC3 and chronic kidney disease.